The drug, IGN311, targets cancer of the tissue that covers organs, and is applicable to breast, colon, gastric and pancreatic cancers.
Twelve patients with epithelial cancers (breast, colorectal, gastric and pancreatic) were studied. The antibody was generally well tolerated, and the capacity of the antibody to destroy tumor cells was significantly induced by IGN311 infusions.
“We are quite pleased with both the favorable safety profile and the anti-tumor activity demonstrated in this study. These results provide us with confidence as we initiate new studies with the compound,” said Dr Patrick Mooney, President and CEO of Aphton Corporation.